ADC Therapeutics (ADCT) has drawn fresh attention after reporting statistically significant Phase 3 LOTIS-5 topline data for ZYNLONTA plus rituximab in relapsed or refractory diffuse large B cell lymphoma, including improved progression free survival versus standard therapy.

Despite the encouraging LOTIS-5 data, the stock’s 1-day share price return fell 21.97%, extending a 7-day share price decline of 69.71% and a 1-year total shareholder return decline of 71.93%. This points to fading momentum and heightened risk perceptions around the story.

If today’s move has you reviewing your biotech exposure, it may be worth broadening your search to other healthcare names using our screener of 39 healthcare AI stocks

With ADC Therapeutics trading at US$1.03 after steep recent declines and analyst targets sitting higher at US$5.60, you have to ask yourself: is this weakness opening a window, or is the market already discounting future growth?

Most Popular Narrative: 86.3% Undervalued

At $1.03, the most followed narrative pegs ADC Therapeutics' fair value at $7.50, putting a large gap between model assumptions and the current share price.

Recent clinical results from the LOTIS-7 and LOTIS-5 trials show ZYNLONTA-based combinations with glofitamab and rituximab achieving high complete response rates and durable efficacy, setting the stage for regulatory approvals and expansion into earlier DLBCL lines and indolent lymphomas, which should drive significant revenue growth.

Want to see why this narrative leans so heavily on rapid revenue expansion, slimmer margins and a richer future earnings multiple, all baked into one valuation story?

Result: Fair Value of $7.50 (UNDERVALUED)

However, this narrative could be knocked off course if ZYNLONTA stumbles in clinical or regulatory review, or if continued losses force heavier dilution for shareholders.

Next Steps

The combination of sharp share price declines, ambitious growth assumptions and real trial progress makes this a complex story. Review the data now and weigh both sides of the thesis by checking the 3 key rewards and 3 important warning signs

Looking for more investment ideas?

If this story has sharpened your thinking, do not stop here. Use curated stock lists to spot opportunities that match your risk and return preferences.

• Chase potential upside in smaller companies by scanning 24 elite penny stocks with strong financials that already show stronger financial characteristics than the typical microcap.
• Zero in on value opportunities by reviewing 49 high quality undervalued stocks where quality fundamentals and pricing appear to line up more attractively.
• Prioritise resilience by focusing on 64 resilient stocks with low risk scores that score well on balance sheet strength and business stability.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.